These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
818 related articles for article (PubMed ID: 33549192)
1. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192 [TBL] [Abstract][Full Text] [Related]
2. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193 [TBL] [Abstract][Full Text] [Related]
3. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Kimball AB; Jemec GBE; Sayed CJ; Kirby JS; Prens E; Ingram JR; Garg A; Gottlieb AB; Szepietowski JC; Bechara FG; Giamarellos-Bourboulis EJ; Fujita H; Rolleri R; Joshi P; Dokhe P; Muller E; Peterson L; Madden C; Bari M; Zouboulis CC Lancet; 2024 Jun; 403(10443):2504-2519. PubMed ID: 38795716 [TBL] [Abstract][Full Text] [Related]
5. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013 [TBL] [Abstract][Full Text] [Related]
7. Bimekizumab versus Adalimumab in Plaque Psoriasis. Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379 [TBL] [Abstract][Full Text] [Related]
8. Bimekizumab versus Secukinumab in Plaque Psoriasis. Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380 [TBL] [Abstract][Full Text] [Related]
9. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Papp KA; Weinberg MA; Morris A; Reich K Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359 [TBL] [Abstract][Full Text] [Related]
11. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974 [TBL] [Abstract][Full Text] [Related]
12. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K; Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109 [TBL] [Abstract][Full Text] [Related]
13. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. van der Heijde D; Gensler LS; Deodhar A; Baraliakos X; Poddubnyy D; Kivitz A; Farmer MK; Baeten D; Goldammer N; Coarse J; Oortgiesen M; Dougados M Ann Rheum Dis; 2020 May; 79(5):595-604. PubMed ID: 32253184 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study. Papp K; Warren RB; Green L; Reich K; Langley RG; Paul C; Asahina A; Johnson L; Arora V; Osuntokun O; Lebwohl M Lancet Rheumatol; 2023 Sep; 5(9):e542-e552. PubMed ID: 38251498 [TBL] [Abstract][Full Text] [Related]
16. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Ritchlin CT; Kavanaugh A; Merola JF; Schett G; Scher JU; Warren RB; Gottlieb AB; Assudani D; Bedford-Rice K; Coarse J; Ink B; McInnes IB Lancet; 2020 Feb; 395(10222):427-440. PubMed ID: 32035552 [TBL] [Abstract][Full Text] [Related]
17. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Oliver R; Krueger JG; Glatt S; Vajjah P; Mistry C; Page M; Edwards H; Garcet S; Li X; Dizier B; Maroof A; Watling M; El Baghdady A; Baeten D; Ionescu L; Shaw S Br J Dermatol; 2022 Apr; 186(4):652-663. PubMed ID: 34687214 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB; Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739 [TBL] [Abstract][Full Text] [Related]
19. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials. Wang Y; Li S; Bai J; Cai X; Tang S; Lin P; Sun Q; Qiao J; Fang H Ther Adv Chronic Dis; 2023; 14():20406223231163110. PubMed ID: 37051072 [TBL] [Abstract][Full Text] [Related]
20. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]